NEW CEO AND CHAIRMAN OF THE BOARD IN SCN

(NGM:SCN)

At the statutory Board meeting in Scandinavian Clinical Nutrition AB (SCN) on Friday, May 23, CEO Ulf Söderberg was elected Chairman of the Board, and CFO Thomas Christensen was appointed new CEO. The former Chairman, Carsten Waern, becomes deputy Chairman of the Board and special advisor to the management.

“SCN is now moving into a new phase, and the new management constellation reflects this change”, says Thomas Christensen. “During the first expansive years we have built an interesting product portfolio and established important networks within R&D and sales. Now we need to make these underlying values visible to the market, and I look forward to working together with Ulf Söderberg in doing this.”

Thomas Christensen has extensive experience from building companies with an international profile and has held several positions as CEO and CFO in both Norwegian and international companies. Ulf Söderberg has many years of experience from entrepreneurship, the stock market and the nutrition industry.

“SCN has substantial values in the company’s product portfolio and pipeline. I look forward to working together with the company’s experienced management on developing these values further by brand building and recognition and not least by presenting our business case to the financial market”, says Ulf Söderberg.

The former Chairman of the Board, Carsten Waern, becomes deputy Chairman of the Board and special advisor to the management. Carsten Waern has an extensive international network within marketing and product development, and many years of experience of the international nutrition business.

For more information, please contact:

Thomas Christensen, CEO, tc@scnutrition.com, +47 922 55 444

Ulf Söderberg, Chairman of the Board, us@scnutrition.com, +46 708 13 22 81

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).